<DOC>
	<DOC>NCT00634504</DOC>
	<brief_summary>The purpose of this study is to investigate whether the administration of Voraxaze reduces exposure to leucovorin and its active metabolite to below the level achieved in patients who have not received Voraxaze.</brief_summary>
	<brief_title>Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Receiving Highdose methotrexate (HDMTX) with or without risk of methotrexate (MTX) toxicity, impaired renal function, and delayed MTX elimination Require intravenous leucovorin Arm A only: allergic reactions to lactose Arm A only: hereditary fructose or galactose intolerance Arm B only: delayed elimination of MTX</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>high dose methotrexate</keyword>
	<keyword>Voraxaze</keyword>
	<keyword>leucovorin</keyword>
	<keyword>delayed elimination</keyword>
	<keyword>methotrexate toxicity</keyword>
	<keyword>rescue</keyword>
	<keyword>renal insufficiency</keyword>
</DOC>